|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CYGB |
Gene summary for CYGB |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CYGB | Gene ID | 114757 |
| Gene name | cytoglobin | |
| Gene Alias | HGB | |
| Cytomap | 17q25.1 | |
| Gene Type | protein-coding | GO ID | GO:0001666 | UniProtAcc | A0A1K0FUB6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 114757 | CYGB | C04 | Human | Oral cavity | OSCC | 4.41e-02 | 1.83e-01 | 0.2633 |
| 114757 | CYGB | C21 | Human | Oral cavity | OSCC | 4.30e-13 | 6.83e-01 | 0.2678 |
| 114757 | CYGB | C30 | Human | Oral cavity | OSCC | 4.51e-04 | 5.07e-01 | 0.3055 |
| 114757 | CYGB | C38 | Human | Oral cavity | OSCC | 7.72e-03 | 4.62e-01 | 0.172 |
| 114757 | CYGB | C51 | Human | Oral cavity | OSCC | 1.29e-05 | 2.52e-01 | 0.2674 |
| 114757 | CYGB | C08 | Human | Oral cavity | OSCC | 1.03e-07 | 2.41e-01 | 0.1919 |
| 114757 | CYGB | LN46 | Human | Oral cavity | OSCC | 6.46e-03 | 8.95e-02 | 0.1666 |
| 114757 | CYGB | ATC12 | Human | Thyroid | ATC | 1.13e-11 | 2.85e-01 | 0.34 |
| 114757 | CYGB | ATC13 | Human | Thyroid | ATC | 4.54e-53 | 1.24e+00 | 0.34 |
| 114757 | CYGB | ATC4 | Human | Thyroid | ATC | 1.06e-14 | 3.81e-01 | 0.34 |
| 114757 | CYGB | ATC5 | Human | Thyroid | ATC | 5.98e-58 | 1.30e+00 | 0.34 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000166731 | Thyroid | ATC | ameboidal-type cell migration | 228/6293 | 475/18723 | 3.72e-11 | 1.22e-09 | 228 |
| GO:001076116 | Thyroid | ATC | fibroblast migration | 32/6293 | 47/18723 | 1.42e-06 | 1.77e-05 | 32 |
| GO:000963634 | Thyroid | ATC | response to toxic substance | 119/6293 | 262/18723 | 4.30e-05 | 3.48e-04 | 119 |
| GO:199074833 | Thyroid | ATC | cellular detoxification | 58/6293 | 116/18723 | 1.88e-04 | 1.26e-03 | 58 |
| GO:001076211 | Thyroid | ATC | regulation of fibroblast migration | 23/6293 | 36/18723 | 1.94e-04 | 1.30e-03 | 23 |
| GO:009723733 | Thyroid | ATC | cellular response to toxic substance | 61/6293 | 124/18723 | 2.31e-04 | 1.49e-03 | 61 |
| GO:009886932 | Thyroid | ATC | cellular oxidant detoxification | 51/6293 | 101/18723 | 3.29e-04 | 2.05e-03 | 51 |
| GO:00329633 | Thyroid | ATC | collagen metabolic process | 52/6293 | 104/18723 | 3.94e-04 | 2.38e-03 | 52 |
| GO:004001316 | Thyroid | ATC | negative regulation of locomotion | 160/6293 | 391/18723 | 1.36e-03 | 7.07e-03 | 160 |
| GO:003033616 | Thyroid | ATC | negative regulation of cell migration | 142/6293 | 344/18723 | 1.64e-03 | 8.22e-03 | 142 |
| GO:005127117 | Thyroid | ATC | negative regulation of cellular component movement | 150/6293 | 367/18723 | 1.99e-03 | 9.54e-03 | 150 |
| GO:200014617 | Thyroid | ATC | negative regulation of cell motility | 147/6293 | 359/18723 | 2.01e-03 | 9.60e-03 | 147 |
| GO:00329641 | Thyroid | ATC | collagen biosynthetic process | 27/6293 | 51/18723 | 3.41e-03 | 1.52e-02 | 27 |
| GO:009875433 | Thyroid | ATC | detoxification | 66/6293 | 152/18723 | 7.23e-03 | 2.85e-02 | 66 |
| GO:00107121 | Thyroid | ATC | regulation of collagen metabolic process | 24/6293 | 47/18723 | 9.99e-03 | 3.64e-02 | 24 |
| GO:00193959 | Thyroid | ATC | fatty acid oxidation | 46/6293 | 103/18723 | 1.26e-02 | 4.42e-02 | 46 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CYGB | SNV | Missense_Mutation | novel | c.69N>C | p.Glu23Asp | p.E23D | Q8WWM9 | protein_coding | tolerated(0.41) | benign(0.204) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response |
| CYGB | deletion | Frame_Shift_Del | novel | c.460delN | p.Leu154CysfsTer9 | p.L154Cfs*9 | Q8WWM9 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| CYGB | SNV | Missense_Mutation | novel | c.244N>A | p.Ala82Thr | p.A82T | Q8WWM9 | protein_coding | deleterious(0) | possibly_damaging(0.764) | TCGA-EA-A5ZE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| CYGB | SNV | Missense_Mutation | novel | c.58N>G | p.Ser20Ala | p.S20A | Q8WWM9 | protein_coding | deleterious(0.03) | benign(0.007) | TCGA-ZJ-AB0H-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
| CYGB | insertion | Frame_Shift_Ins | novel | c.28_29insGGGG | p.Ile10ArgfsTer90 | p.I10Rfs*90 | Q8WWM9 | protein_coding | TCGA-DS-A1OD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | ||
| CYGB | SNV | Missense_Mutation | c.463N>T | p.Arg155Cys | p.R155C | Q8WWM9 | protein_coding | tolerated(0.07) | benign(0.003) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CYGB | SNV | Missense_Mutation | novel | c.563N>T | p.Ser188Leu | p.S188L | Q8WWM9 | protein_coding | deleterious_low_confidence(0.01) | benign(0.116) | TCGA-A6-6141-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | 5-fu | SD |
| CYGB | SNV | Missense_Mutation | rs369705030 | c.277G>A | p.Val93Met | p.V93M | Q8WWM9 | protein_coding | deleterious(0) | probably_damaging(0.944) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| CYGB | SNV | Missense_Mutation | c.34C>T | p.Arg12Cys | p.R12C | Q8WWM9 | protein_coding | deleterious(0.02) | possibly_damaging(0.66) | TCGA-CK-5913-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| CYGB | SNV | Missense_Mutation | c.143G>T | p.Arg48Met | p.R48M | Q8WWM9 | protein_coding | deleterious(0.01) | probably_damaging(0.921) | TCGA-D5-6930-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |